Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
Titel:
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
Auteur:
Telli, Melinda L. Hellyer, Jessica Audeh, William Jensen, Kristin C. Bose, Shikha Timms, Kirsten M. Gutin, Alexander Abkevich, Victor Peterson, Rebecca N. Neff, Chris Hughes, Elisha Sangale, Zaina Jones, Joshua Hartman, Anne-Renee Chang, Pei-Jen Vinayak, Shaveta Wenstrup, Richard Ford, James M.